SCHEMBL7366713

SCHEMBL7366713

C1=C\N=C/C=N\C=C/1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7366720 1.00
SCHEMBL31676163 0.91
SCHEMBL18320895 0.82
SCHEMBL460688 0.82
SCHEMBL30401686 0.82
SCHEMBL460689 0.82
SCHEMBL31675822 0.82
SCHEMBL12079525 0.80
SCHEMBL12079523 0.80
Hydrochloric Acid SCHEMBL38657456 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4628519-A1 ORGANOGERMANIUM(IV) CARBOXYLATES AND MIXTURES OF GERMANIUM CARBOXYLATES WITH ORGANIC ACID ANHYDRIDES AS CATALYSTS Technische Universität Graz (AT) 2025-10-08 EP disclosed
WO-2023165987-A1 PRECURSOR MARKERS AND RADIOTRACERS WITH THREE OR MORE TARGETING VECTORS FOR THERANOSTICS USED IN NUCLEAR MEDICINE Atoms for Cure GmbH (DE) 2023-09-07 WO disclosed
US-20230242546-A1 SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS SUDO BIOSCIENCES LIMITED (GB) 2023-08-03 US disclosed
WO-2023118195-A1 FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS Atoms for Cure GmbH (DE) 2023-06-29 WO disclosed
US-20230126662-A1 SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-04-27 US disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
US-20210147478-A1 INHIBITORS OF BLOOD COAGULATION FACTOR XIII ZEDIRA GMBH (DE) 2021-05-20 US disclosed
US-10913710-B2 Benzene disulfonamide for the treatment of cancer MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) 2021-02-09 US disclosed
US-20210002254-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-01-07 US disclosed
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-09-08 US disclosed
US-9780310-B2 Heterocyclic compound for organic electroluminescent device and its application TOSOH CORPORATION (JP) 2017-10-03 US disclosed
US-20170217930-A1 PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES BRISTOL-MEYERS SQUIBB COMPANY (US) 2017-08-03 US disclosed
EP-2457913-B1 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARM LLC (US) 2017-04-19 EP disclosed
EP-1973887-B1 AZA HETEROCYCLICS FOR THE TREATMENT OF MALARIA OR AIDS IMMUPHARMA FRANCE SA (FR) 2012-09-19 EP disclosed
US-5539104-A 1,4 Diazocines as fibrinogen antagonists SMITHKLINE BEECHAM CORP. (US) 1996-07-23 US disclosed
US-5539104-A 1,4 Diazocines as fibrinogen antagonists SMITHKLINE BEECHAM CORP. (US) 1996-07-23 US disclosed
EP-0610432-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-08-17 EP disclosed
EP-0610432-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1994-08-17 EP disclosed
WO-1993009133-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-05-13 WO disclosed
WO-1993009133-A1 C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1993-05-13 WO disclosed